Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy

At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S (NYSE:NVO) shared an abstract with data from the company’s next-generation weight loss candidate, amycretin.

Earlier today, Novo Nordisk announced that its weight-loss drug liraglutide is safe and effective for children as young as six.

The company-funded study revealed a 7.4% reduction in body mass index for children aged 6 to 12 who used the injectable pens over a year compared to a placebo group.

Amycretin is a novel protein-based unimolecular amylin (regulates hunger) and GLP-1 receptor co-agonist for once-daily oral administration.

GLP-1 (produced in the small intestine to regulate blood sugar) is the same hormone targeted by other weight loss drugs like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide).

In a ...